Dr. Luca Pani is former Director General of the Italian Medicines Agency (AIFA) and a globally recognized expert in psychiatry, pharmacology and molecular biology. As Vice President for Regulatory Strategy and Market Access Innovation, Dr. Pani guides the company’s development of innovative solutions for clinical trials methodologies and health value outcomes.
During his tenure as Director General of AIFA, Dr. Pani pioneered several new approaches to drug approval, pricing, and reimbursement strategies by using advanced informatics to follow and certify real-world data. These models have now been adopted in many other countries. As a European regulator, Dr. Pani has been a leading figure for approval and scientific advice for CNS products and served as Chair of both the European Union Board Telematics Committee and of the European Risk Management Strategy Facilitation Group. He has authored or co-authored hundreds of publications and served on the editorial boards of many scientific journals, including Clinical Neuropsychiatry. He is Professor of Clinical Psychiatry at the University of Miami.
Dr. Pani earned his medical degree from the University of Cagliari, psychiatry degree from the University of Naples and completed post-doctoral training in molecular biology and pharmacology at the University of Illinois at Chicago and Georgetown University.